A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) QID and Vehicle Ophthalmic Solution QID in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-23.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Dry Eye Syndromes · Aldeyra Therapeutics, Inc..
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 3rd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc. is open now. The open studies under Dry Eye Syndromes, anywhere →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 7
First in 2017; this study’s year is marked. 2 started in 2019.
This study's enrollment of 422 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 206 across the 13 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Reproxalap Ophthalmic Solution (0.25%) QID
Drug: Vehicle Ophthalmic Solution QID
Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID
Drug: Vehicle Ophthalmic Solution QID to BID
Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
Vehicle Ophthalmic Solution administered QID for twelve weeks
Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))
Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort - 100 = maximal discomfort), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.
Time frame: The efficacy assessment period (Day 1 through 85) was assessed at Weeks 1, 2, 4, 6, 8, 10, and 12; baseline was Day 1.
Fluorescein Nasal Region Score (0 = None - 4 = Severe)
Change from baseline comparison of reproxalap to vehicle for fluorescein staining of the nasal region (0 = none - 4 = severe), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline fluorescein nasal score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.
Time frame: The efficacy assessment period (Day 15 through 85) was assessed at Weeks 2, 4, 6, 8, 10, and 12; baseline was Day 1.
| Milestone | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID |
|---|---|---|---|---|
| Started | 105 | 106 | 105 | 106 |
| Completed | 98 | 102 | 94 | 104 |
| Not completed | 7 | 4 | 11 | 2 |
Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort - 100 = maximal discomfort), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.
| score on a scale | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID |
|---|---|---|---|---|
| Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) | -11.5 ± 2.44 | -15.0 ± 2.39 | -17.8 ± 2.20 | -6.8 ± 2.12 |
Change from baseline comparison of reproxalap to vehicle for fluorescein staining of the nasal region (0 = none - 4 = severe), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline fluorescein nasal score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.
| units on a scale | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID |
|---|---|---|---|---|
| Fluorescein Nasal Region Score (0 = None - 4 = Severe) | -0.47 ± 0.060 | -0.46 ± 0.058 | -0.53 ± 0.056 | -0.46 ± 0.053 |
Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately three months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap Ophthalmic Solution (0.25%) QID | 0/105 (0%) | 3/105 (2.9%) | 88/105 (83.8%) |
| Vehicle Ophthalmic Solution QID | 0/106 (0%) | 3/106 (2.8%) | 7/106 (6.6%) |
| Reproxalap Ophthalmic Solution (0.25%) QID to BID | 0/105 (0%) | 1/105 (1%) | 94/105 (89.5%) |
| Vehicle Ophthalmic Solution QID to BID | 0/106 (0%) | 2/106 (1.9%) | 1/106 (0.9%) |
| Event | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/105 | 0/106 | 1/105 | 0/106 |
| Gastroenteritis salmonellaInfections and infestations | 1/105 | 0/106 | 0/105 | 0/106 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/105 | 0/106 | 0/105 | 0/106 |
| PneumoniaInfections and infestations | 1/105 | 0/106 | 0/105 | 0/106 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/105 | 0/106 | 0/105 | 1/106 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/105 | 1/106 | 0/105 | 0/106 |
| Cerebrovascular accidentNervous system disorders | 0/105 | 0/106 | 0/105 | 1/106 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/105 | 1/106 | 0/105 | 0/106 |
| OsteomyelitisInfections and infestations | 0/105 | 1/106 | 0/105 | 0/106 |
| Event | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID |
|---|---|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 88/105 | 7/106 | 94/105 | 1/106 |
| Age, Categorical(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 50 | 43 | 49 | 182 |
| >=65 years | 65 | 56 | 62 | 57 | 240 |
| Sex: Female, Male(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| Female | 78 | 77 | 75 | 82 | 312 |
| Male | 27 | 29 | 30 | 24 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 8 | 8 | 33 |
| Not Hispanic or Latino | 96 | 98 | 97 | 98 | 389 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 0 | 0 | 3 |
| Asian | 4 | 4 | 8 | 9 | 25 |
| Black or African American | 7 | 7 | 6 | 7 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| White | 92 | 91 | 90 | 90 | 363 |
| Multiple | 1 | 0 | 0 | 0 | 1 |
| Other | 1 | 0 | 1 | 0 | 2 |
| Region of Enrollment(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| United States | 105 | 106 | 105 | 106 | 422 |
| Iris Color (Right Eye)(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| Black | 1 | 1 | 0 | 1 | 3 |
| Blue | 32 | 38 | 34 | 26 | 130 |
| Brown | 41 | 37 | 44 | 53 | 175 |
| Hazel | 18 | 20 | 13 | 12 | 63 |
| Gray | 1 | 0 | 0 | 2 | 3 |
| Green | 12 | 10 | 14 | 12 | 48 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Iris Color (Left Eye)(Participants) | Reproxalap Ophthalmic Solution (0.25%) QID | Vehicle Ophthalmic Solution QID | Reproxalap Ophthalmic Solution (0.25%) QID to BID | Vehicle Ophthalmic Solution QID to BID | Total |
|---|---|---|---|---|---|
| Black | 1 | 1 | 0 | 1 | 3 |
| Blue | 32 | 38 | 34 | 26 | 130 |
| Brown | 41 | 37 | 44 | 53 | 175 |
| Hazel | 18 | 20 | 13 | 12 | 63 |
| Gray | 1 | 0 | 0 | 2 | 3 |
| Green | 12 | 10 | 14 | 12 | 48 |
| Other | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Oct 2019, 5 months.
Results were first posted in Jan 2025, 5 years 3 months after primary completion. A results delay was requested in Dec 2020.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.